Background Currently, crizotinib is the only drug that has been approved for treatment of
ALK-rearranged non-small-cell lung cancer (NSCLC). We aimed to study the activity and …

Abstract Crizotinib (PF02341066, Xalkori; Pfizer) was recently approved by the US Food and
Drug Administration for treatment of ALK-positive non–small cell lung cancer (NSCLC) as …

Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-
line treatment in patients with anaplastic lymphoma kinase (ALK)–positive advanced …

Purpose Crizotinib confers improved progression-free survival compared with chemotherapy
in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but …

Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …

ABSTRACT Background Approximately 3–5% of NSCLC harbors ALK gene
rearrangements. Crizotinib is a first-in-class, oral, small-molecule competitive ALK inhibitor …

Background In single-group studies, chromosomal rearrangements of the anaplastic
lymphoma kinase gene (ALK) have been associated with marked clinical responses to …

Background Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements
generally have a progression-free survival of 8–11 months while on treatment with the ALK …

Background ALK gene rearrangement defines a new molecular subtype of non-small-cell
lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor …

Background ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK
tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably …